Theranostic nanoparticles for the treatment of RAI refractory thyroid cancer

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): Site-specific delivery of drugs while minimizing unwanted distribution has been one of the pursued goals in cancer therapy. In this endeavor, we have developed polymer-based drug delivery carriers, whose distribution in vivo can also be quantitatively imaged by MRI, enabling whole body, real-time mapping of drug distribution, and measurements of pharmacokinetic, pharmacodynamic, and toxicity profiles. Two innovative aspects in this proposal are 1) polymeric drug carriers with exceptional stability, large retention capacity of drugs, and versatility in assembly with diverse cancer drugs and targeting ligands and 2) novel MRI techniques for quantitative measurement of paramagnetic contrast agents in the body. These aspects fulfill the requirement for drug delivery carriers to be 'theranostic'. Motivated by our recent findings that a molecule called the intercellular adhesion molecule (ICAM)-1 is highly expressed in correlation with the malignancy of thyroid cancer, we propose to develop the theranostic drug carriers loaded with Paclitaxel as a new treatment modality of thyroid cancer. Two specific aims that will be achieved in this proposal are: 1) Develop comprehensive protocols for production and validation of theranostic nanoparticles, and for in vitro evaluation of drug efficacy and imaging techniques; 2) Determine spatiotemporal distribution of drug carriers, and therapeutic efficacy and toxicity profiles to quantitatively assss tumor-drug interactions. Overall, theranostic capability of our drug carriers will be demonstrated in ectopic and orthotopic xenografts of human thyroid carcinomas in mice, a study designed to validate developed drug carriers for future use to treat aggressive, metastatic, and radioactive iodine refractory thyroid cancer.